Huyabio International Announces Global Clinical Trial Collaboration With Bristol Myers Squibb In Melanoma

<br /> Huyabio International Announces Global Clinical Trial Collaboration With Bristol Myers Squibb In Melanoma<br />

Global Phase 3 pivotal trial to combine HUYABIO’s HBI-8000 with Opdivo® (nivolumab) in melanoma

PR Newswire

SAN DIEGO

,

March 30, 2021

/PRNewswire/ — HUYABIO International (HUYABIO™), the leader in accelerating global development of

China’s

pharmaceutical innovations, today announced that it had entered into a clinical collaboration agreement with Bristol-Myers Squibb Company (NYSE: BMY) to evaluate the combination of HUYABIO’s HBI-8000, an epigenetic immunomodifier, and

Opdivo

® (nivolumab), a PD-1 blocking antibody. The Phase 3 trial is designed to evaluate the safety and efficacy of the combination in subjects with unresectable or metastatic melanoma not previously treated with anti-PD-1 therapy.

“This Phase 3 trial follows our open label Phase 2 study which showed impressive clinical results for the combination of

Opdivo

and HBI-8000 to treat melanoma,” said Dr.

Mireille Gillings

, CEO & Executive Chair of HUYABIO. “HBI-8000 has been shown to enhance the efficacy of

Opdivo

through one of its mechanisms of action that controls acetylation and nuclear transportation of PD-L1.”

HUYABIO will be the sponsor of the trial. Bristol

Myers Squibb

will provide

Opdivo

clinical drug supply for the study.

Opdivo

® is a registered trademark of Bristol Myers Squibb.

About HBI-8000

HBI-8000 is an epigenetic immunomodulator approved for the treatment of lymphoma and metastatic breast cancer in

China

. This oral agent targets class I histone deacetylases causing cell cycle arrest and tumor cell death as the mechanism underlying its single agent activity against lymphoma. The drug also has immunomodulatory impact by increasing the efficacy of checkpoint inhibitors in preclinical animal models. The Company recently reported results from its ongoing Phase 2 study for the nivolumab combination demonstrating an overall objective response rate above 70% with a disease control rate over 90% in a cohort of checkpoint naïve patients with melanoma.

About HUYABIO International

HUYABIO is the leader in accelerating the global development of novel biopharmaceutical product opportunities originating in

China

enabling faster, more cost effective and lower-risk drug development in global markets. Through extensive collaboration with biopharmaceutical, academic and commercial organizations, it has built the largest

China

-sourced compound portfolio covering all therapeutic areas. With offices in the US,

Japan

,

South Korea

,

Canada

,

Ireland

and eight strategic locations across

China

, the Company has become a partner of choice to accelerate product development and maximize value globally. For more information, please visit

www.huyabio.com

.